Clinical Trial

Etodolac Nanogel as an Adjunct to Physiotherapy for Knee Osteoarthritis

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 29, 2025 (before its estimated February 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
Brief Summary: Knee osteoarthritis (OA) is a common, disabling condition affecting the weight-bearing knee joint, leading to pain, reduced function, and muscle weakness, particularly of the quadriceps. Strengthening exercises are recommended to improve joint stability, physical function, and slow disease progression. Etodolac, a selective NSAID approved for osteoarthritis, has proven analgesic and anti-inflammatory effects. This study investigates the adjunctive effect of a topical Etodolac-loaded solid lipid nanoparticle gel combined with traditional physiotherapy in patients with knee OA. Thirty patients with mild to moderate unilateral tibiofemoral OA will be randomized into two groups: traditional physiotherapy alone or physiotherapy plus Etodolac gel. Outcomes including pain, knee function, functional performance, quadriceps strength, and proprioception will be assessed at baseline and after four weeks. The study aims to determine whether adding topical Etodolac enhances the benefits of standard physiotherapy in managing knee OA.
Trial Details
NCT Number NCT07308470
Lead Sponsor Pharos University in Alexandria
Conditions Knee Osteoarthritis
Enrollment 30 participants
Start Date 2026-01-08
Primary Completion 2026-02-07 (estimated)
Study Completion 2026-03-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-29